GLOW Stack

The GLOW stack combines three peptides with distinct, complementary mechanisms. No published study has characterized the combination itself, so the rationale below is component-level.

**GHK-Cu (copper tripeptide-1)** • A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine). • In lab and skin models it supports collagen and elastin production, angiogenesis and antioxidant defense, and modulates wound-healing-associated gene expression (Pickart & Margolina, 2018).

**BPC-157 (pentadecapeptide)** • Synthetic 15-amino-acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; PubChem CID 108101). • Proposed preclinical mechanisms center on nitric-oxide signaling and the VEGFR2-Akt-eNOS axis, plus FAK-paxillin-mediated fibroblast migration.

**TB-500 (thymosin beta-4 fragment)** • A short synthetic fragment (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4 (a 43-aa native protein); not chemically identical to full Tb4. • Acts mainly by sequestering G-actin, promoting cell migration and angiogenesis (the LKKTET motif is critical).

The marketed premise is that skin remodeling (GHK-Cu) plus soft-tissue repair (BPC-157, TB-500) act synergistically. Synergy has not been demonstrated for this blend.

**Bottom line: no human clinical trial has evaluated the GLOW blend.** Evidence is component-level and uneven:

• **GHK-Cu** has the most human data of the three, but it is overwhelmingly from topical/cosmetic use (skin firmness, fine lines, wound support). Injectable GHK-Cu has little controlled human evidence. • **BPC-157** evidence is almost entirely preclinical (in vitro and rodent). Reviews note a generally favorable preclinical safety profile but no completed human efficacy trials (Jozwiak et al., 2025). • **TB-500** itself has essentially no dedicated human trials. Most data come from the parent protein, thymosin beta-4, in animal models (e.g., cardiac and tissue repair; Bock-Marquette et al., 2004). The Tb4 ophthalmic candidate (RGN-259) reached Phase 3, but that program is not TB-500 and not this blend.

Reader takeaway: treat efficacy claims for GLOW as hypothesis-generating, not established.

PeptideSciences101 does not publish dosing protocols for unapproved injectable peptides.

For reference only, GLOW is commonly *sold* as a single lyophilized vial in an approximate 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 ratio. This describes how vendors package the product; it is not a recommendation, and reconstitution/administration of research chemicals carries unverified purity and sterility risk. Real-world use belongs in the community forum, kept separate from this reference.

GLOW is itself a combination. It can be read as the well-known **BPC-157 + TB-500** recovery pairing with **GHK-Cu** added for skin and collagen effects. Because the three are pre-mixed at a fixed ratio, users cannot titrate components independently — a practical limitation worth noting.

GLOW Stack is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Reported and theoretical risks: • Injection-site reactions (redness, swelling, irritation). • Sourcing risk: research-chemical vials are unregulated for purity, sterility and endotoxins; contamination is a real concern. • Angiogenesis caution: BPC-157 and TB-500 promote blood-vessel growth, raising theoretical concern for anyone with known or suspected cancer. • Immunogenicity: peptide fragments can provoke immune responses (a concern the FDA cited for this class). • Unknown long-term safety: no long-term human data for any component as an injectable, and none for the blend. • Sport: TB-500/thymosin beta-4 is WADA-prohibited; BPC-157 has anti-doping history — see regulatory notes.

• **Local:** injection-site redness, swelling or irritation. • **Sourcing/quality:** research-chemical vials are not regulated for purity, sterility or endotoxin content; contamination is a genuine risk. • **Angiogenesis/cancer caution:** BPC-157 and TB-500 promote blood-vessel formation; theoretical concern for anyone with known or suspected malignancy. • **Immunogenicity:** peptide fragments may trigger immune reactions — a concern the FDA cited when restricting this class. • **Pregnancy/breastfeeding:** thymosin beta-4 has developmental roles; avoid. • **Anti-doping:** TB-500/thymosin beta-4 is WADA-prohibited (S2); BPC-157 has anti-doping history (verify current status). Tested athletes should treat GLOW as prohibited. • **Long-term safety:** no long-term human data for any component as an injectable, and none for the blend.

Member experiences with GLOW are collected in the community forum and are anecdotal: reports range from noticeable skin and recovery improvements to no effect, and outcomes vary with sourcing and individual factors. These accounts are kept separate from the evidence above and are not proof of efficacy or safety.